Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Groundbreaking Microarray Immunoassay Simultaneously Detect 30+ Allergens from Single Blood Sample

By LabMedica International staff writers
Posted on 30 Jul 2024

A revolutionary microarray immunoassay enables patients to receive results for multiple allergens using just a single blood sample, thereby minimizing the necessity for multiple tests and appointments. More...

AliveDx’s (Eysins, Switzerland) groundbreaking microarray immunoassay is specifically designed to detect specific IgE antibodies directed against protein allergens in human serum and runs on the company’s proprietary MosaiQ platform. This multiplex immunoassay microarray is capable of detecting over 30 allergens, including those from both inhalants and foods and represents a significant leap in diagnostic capabilities by allowing simultaneous testing for various conditions. This method streamlines the diagnostic process, simplifies laboratory workflows, and reduces the manual labor typically associated with singleplex testing methods. Consequently, it saves significant time for both laboratories and clinicians, enhancing the ability to efficiently diagnose and exclude multiple conditions. For patients who are sensitized to multiple allergens, this technology offers a rapid, comprehensive diagnostic process and supports more targeted treatment approaches.

AliveDx has now received the IVDR CE mark for its microarray immunoassay while the MosaiQ platform is already CE-marked for autoimmune disease screening. This first IVDR CE mark in the allergy category reaffirms AliveDx's commitment to broadening the reach of its MosaiQ platform and to supporting the millions globally who suffer from allergies. This milestone also reinforces the company’s role as a major player in both the allergy and autoimmune markets and highlights the MosaiQ platform’s flexibility and versatility. Going forward, AliveDx plans to expand its panels in both areas and to partner with distributors worldwide.

"The new multiplex immunoassay will provide a detailed analysis of an individual's allergic sensitization by testing specific IgE to a wide array of allergens in a single test," said Christian Fischer, Chief Scientific & Medical Officer at AliveDx. “This comprehensive approach will help optimize laboratory workflows, and help clinicians obtain a complete picture of their patient's atopic sensitization profile.”

“Patients will soon be able to receive results for multiple allergens from a single blood sample, reducing the need for multiple tests and visits,” added Manuel O. Méndez, CEO of AliveDx. “For the medical community, this means having access to an efficient and cost-effective solution, which consolidates multiple tests into one. We look forward to supporting patients around the world, and helping them get appropriate treatment sooner."

Related Links:
AliveDx


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.